Grounds to Challenge a Stop Manufacturing Order Under the Drugs and Cosmetics Act 1940

In the highly regulated pharmaceutical industry in India, receiving a stop manufacturing order can halt operations abruptly, leading to significant financial losses and legal battles. Manufacturers often face such orders under the Drugs and Cosmetics Act, 1940 (and Rules, 1945) for alleged violations like stocking or manufacturing drugs without proper licenses. But what are the grounds to challenge a stop manufacturing order? This post explores the legal framework, key case precedents, and practical strategies, drawing from judicial interpretations.

If you're a manufacturer wondering, What are the grounds to challenge a stop manufacturing order under the Drugs and Cosmetics Act 1945?, read on for a detailed breakdown. Note: This is general information based on legal precedents and not specific legal advice. Consult a qualified lawyer for your case.

Understanding Stop Manufacturing Orders and Section 18(c)

A stop manufacturing order typically arises from inspections revealing potential contraventions of Section 18(c) of the Drugs and Cosmetics Act, 1940, which prohibits the manufacture, sale, stocking, or exhibition for sale of drugs without a valid license. Paired with Rule 62(d) of the Drugs and Cosmetics Rules, 1945, it mandates that drugs be supplied only against signed orders, emphasizing proper documentation.

Such orders are often precursors to criminal complaints under Section 27(d), punishable by imprisonment and fines. However, courts have consistently held that not every inspection finding justifies a blanket halt or prosecution. Mere possession or storage without evidence of sale or intent to sell does not automatically constitute an offence. 1974 0 Supreme(SC) 27

Unless it is for purpose of sale, does not amount to an offence within meaning of Section 18 of Drugs and Cosmetics Act.

This principle forms the bedrock for challenging such orders.

Primary Grounds to Challenge: Lack of Evidence of Offence

1. Insufficient Proof of Sale or Sale Intent

The cornerstone of any valid complaint or stop order under Section 18(c) is clear evidence linking the accused to sale, stocking for sale, or manufacturing intent without a license. Courts have quashed proceedings where prosecutors relied solely on possession.

In one key ruling, the court clarified:

No stock of impugned substance was found on premise of Appellants – Alleged substance is not included as a drug in Indian Pharmacopoeia – No scientific evidence or otherwise has been furnished to prove that alleged substance is solely used for manufacturing drug and not food items. 2023 1 Supreme 730

Other sources reinforce this: Violations under Section 18(c) and Rule 65(5)(1)(e) require proof of unlicensed manufacturing or sale, such as failure to produce purchase bills or signed orders. 2023 Supreme(Online)(MAD) 24779 Without scientific or material evidence proving the substance's drug nature and sale intent, challenges succeed. 2023 1 Supreme 730

• Bullet point takeaway: Challenge on grounds of no recovered stock, unclassified substances, or dual-use materials (e.g., for food).
• Related rule: Rule 65 mandates licensing for manufacturing; non-compliance needs intent proof. 2024 0 Supreme(Mad) 1043

2. Mere Possession or Storage is Not Enough

Judicial precedent emphasizes that stocking alone, without sale evidence, falls short:

Stocked for sale there and then? or to be sold certainly but elsewhere later? are two alternatives flowing from language of Section 18(1)(c). 1974 0 Supreme(SC) 4

A pending license application does not permit manufacturing or sale, but absence of sale proof weakens the case. 1974 0 Supreme(SC) 4Additional insights from cases show prosecutions fail without linking to Schedule H drugs or proper records under Rule 62(d). 2020 0 Supreme(Mad) 2309

Procedural Lapses: A Strong Defense Pillar

Procedural defects often invalidate stop orders and complaints. Courts scrutinize:

1. Limitation Periods

Complaints must be filed within the three-year limitation under CrPC Section 468. Delays bar prosecution:

Prosecution was barred by law of limitation as complaint was filed beyond three-year period.

02200032906

2. Inadequate Show-Cause Notice

Notices must specify violations clearly, including signed order requirements under Rule 62(d):

The show cause notice did not adequately inform the petitioners of the requirement for signed orders, rendering the prosecution invalid.

02200032906

Cross-references: Inspections under Rule 65 and failures in record maintenance (Section 22(1)(cca)) require proper notice. Lack of address or license details on sales invalidates claims. 2024 0 Supreme(Mad) 1043 2024 Supreme(Online)(Tel) 28557

• Timely filing: Essential for validity.
• Proper notice: Must detail exact rule breaches, e.g., Rule 65(9)(b) for licensee details. 2013 0 Supreme(Mad) 2909

Integrating Manufacturing-Specific Violations

Stop orders often cite manufacturing lapses under Section 18(a)(i)/(vi) or Section 18(c) r/w Rule 105(2). Challenges succeed if:

• No proof of reprocessing without testing (Rule 142(c)). 2013 0 Supreme(Bom) 1850
• Compromise possible post-trial under Sections 18(a)(vi), 18(b). 2018 0 Supreme(Chh) 306
• Directors not vicariously liable without specific roles. 2017 0 Supreme(Raj) 2248

Broader context: Section 28 covers unlawful manufacture, but needs license proof. Rule 65 governs license conditions; breaches like missing bills trigger Section 22(3). 2024 Supreme(Online)(Tel) 28557

Exceptions Where Challenges May Fail

• Proven manufacturing/sale without license, even incomplete. 2020 0 Supreme(Mad) 2309
• Record failures under Rule 62(d)/65, e.g., no purchase bills. 2025 0 Supreme(SC) 250 (implied from patterns)
• Substances confirmed as drugs via pharmacopoeia.

Key Takeaways and Recommendations

To challenge a stop manufacturing order effectively:1. Gather counter-evidence: Prove no sale intent, dual-use substances, or licensing efforts. 1974 0 Supreme(SC) 272. Audit procedures: Check limitation, notice adequacy.

02200032906

References:- 1974 0 Supreme(SC) 27: Storage without sale intent not offence.-

02200032906

Conclusion

Challenging a stop manufacturing order under the Drugs and Cosmetics Act hinges on disproving sale intent, evidentiary gaps, and procedural flaws. Cases like 1974 0 Supreme(SC) 27 2023 1 Supreme 730 show courts favor defendants without solid proof. Manufacturers should prioritize compliance with Sections 18(c), 27(d) and Rules 62/65 to avoid pitfalls.

Stay proactive: Regular audits and legal reviews mitigate risks. This analysis draws from cited precedents; outcomes vary by facts. Always seek professional advice.